NeuroSense Therapeutics Ltd. (NRSN) 10-Year Financial Performance & Capital Metrics

NRSN • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

AboutNeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.Show more

Revenue $0
EBITDA -$10M +17.9%
Net Income -$10M -1.0%
EPS (Diluted) -0.55 +33.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -2880.11% -433.6%
ROIC -
Debt/Equity 0.03
Interest Coverage -31.84 -45.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 36.4% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-2.74%

EPS CAGR

10Y-

5Y-

3Y-

TTM28.57%

ROCE

10Y Avg-340.49%

5Y Avg-381.68%

3Y Avg-481.63%

Latest-861.04%

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	0	3K	3K	89K	97K	22K
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	0	-3K	-3K	-89K	-97K	-22K
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	-	0%	-28.67%	-0.09%	0.77%
Operating Expenses+	1.24M	2.89M	5.59M	13.46M	12.05M	9.88M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	337K	393K	2.5M	7.14M	4.78M	4.2M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	898K	2.5M	3.08M	6.42M	7.27M	5.7M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	0	0	0	-89K	0	-22K
Operating Income+	-1.24M	-2.89M	-5.59M	-13.55M	-12.05M	-9.9M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	-1.34%	-0.93%	-1.43%	0.11%	0.18%
EBITDA+	0	-2.88M	-5.58M	-13.46M	-12.03M	-9.88M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	-	-0.94%	-1.41%	0.11%	0.18%
D&A (Non-Cash Add-back)	1.24M	3K	3K	89K	21K	22K
EBIT	-1.22M	-2.83M	-2.89M	-12.32M	-9.66M	-9.9M
Net Interest Income+	13K	61K	-1.15M	76K	-372K	-309K
Interest Income	18K	61K	0	91K	178K	2K
Interest Expense	5K	0	1.15M	15K	550K	311K
Other Income/Expense	13K	60K	1.55M	1.21M	1.94M	-308K
Pretax Income+	-1.22M	-2.83M	-4.04M	-12.34M	-11.28M	-10.21M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	0	0	0	-1.14M	0	0
Effective Tax Rate %	1%	1%	1%	1%	0.9%	1%
Net Income+	-1.23M	-2.83M	-4.04M	-12.34M	-10.11M	-10.21M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	-1.3%	-0.43%	-2.05%	0.18%	-0.01%
Net Income (Continuing)	-1.22M	-2.83M	-4.04M	-11.2M	-10.11M	-10.21M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.22	-0.51	-0.23	-1.07	-0.83	-0.55
EPS Growth %	-	-1.32%	0.55%	-3.65%	0.22%	0.34%
EPS (Basic)	-0.22	-0.51	-0.23	-1.07	-0.83	-0.55
Diluted Shares Outstanding	5.45M	5.52M	10.86M	11.51M	13.64M	18.6M
Basic Shares Outstanding	5.45M	5.52M	10.86M	11.51M	13.64M	18.6M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	913K	729K	11.41M	7.38M	2.92M	4.4M
Cash & Short-Term Investments	895K	699K	11.06M	7.09M	2.64M	3.38M
Cash Only	895K	699K	11.06M	3.54M	2.64M	3.38M
Short-Term Investments	0	0	0	3.55M	0	0
Accounts Receivable	18K	30K	178K	131K	166K	164K
Days Sales Outstanding	-	-	-	-	-	-
Inventory	-18	-67	-178K	-3.68M	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	18	67	217K	3.71M	40K	35K
Total Non-Current Assets+	42K	50K	19K	329K	269K	173K
Property, Plant & Equipment	7K	13K	19K	306K	238K	150K
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	35K	37K	0	0	22K	23K
Other Non-Current Assets	0	0	0	23K	9K	0
Total Assets+	955K	779K	11.43M	7.71M	3.18M	4.58M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	-0.18%	13.67%	-0.33%	-0.59%	0.44%
Total Current Liabilities+	37K	120K	597K	1.73M	3.46M	1.99M
Accounts Payable	23K	55K	39K	498K	1.46M	1.16M
Days Payables Outstanding	-	6.69K	4.75K	2.04K	5.49K	19.25K
Short-Term Debt	0	0	0	64K	69K	73K
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	5K	29K	443K	349K	545K	188K
Current Ratio	24.68x	6.08x	19.12x	4.28x	0.84x	2.21x
Quick Ratio	24.68x	6.08x	19.41x	6.41x	0.84x	2.21x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	1.83M	365K	1.59M	0
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	147K	73K	0
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	1.83M	218K	1.41M	0
Total Liabilities	37K	120K	2.42M	2.09M	4.94M	1.99M
Total Debt+	0	0	1.83M	211K	142K	73K
Net Debt	-895K	-699K	-9.23M	-3.33M	-2.5M	-3.31M
Debt / Equity	-	-	0.20x	0.04x	-	0.03x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-247.00x	-	-4.84x	-903.47x	-21.91x	-31.84x
Total Equity+	918K	659K	9.01M	5.62M	-1.87M	2.58M
Equity Growth %	-	-0.28%	12.67%	-0.38%	-1.33%	2.38%
Book Value per Share	0.17	0.12	0.83	0.49	-0.14	0.14
Total Shareholders' Equity	918K	659K	9.01M	5.62M	-1.87M	2.58M
Common Stock	1K	1K	0	0	0	0
Retained Earnings	-1.58M	-4.41M	-8.45M	-20.79M	-26.12M	-36.66M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	24.36M	0
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-582K	-695K	-1.54M	-7.59M	-8.35M	-10.13M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	-0.19%	-1.21%	-3.93%	-0.1%	-0.21%
Net Income	-1.22M	-2.83M	-4.04M	-12.34M	-10.11M	-10.21M
Depreciation & Amortization	0	3K	3K	89K	21K	22K
Stock-Based Compensation	611K	2.06M	4.16M	5.11M	1.54M	557K
Deferred Taxes	0	2K	-2.72M	0	0	0
Other Non-Cash Items	0	-2K	791K	-1.19M	-1.71M	277K
Working Capital Changes	29K	71K	273K	750K	1.91M	-781K
Change in Receivables	-3K	-12K	-204K	55K	19K	0
Change in Inventory	3K	0	0	-55K	0	0
Change in Payables	23K	32K	-16K	459K	961K	-299K
Cash from Investing+	-26K	-9K	-17K	-3.54M	3.47M	1K
Capital Expenditures	-7K	-9K	-17K	-70K	-29K	-3K
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	29K	-6K	4K
Cash from Financing+	1.42M	508K	11.9M	3.69M	3.98M	10.91M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	-3K	0	800K	-96K	80K	-391K
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-589K	-704K	-1.56M	-7.66M	-8.38M	-10.14M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	-0.2%	-1.21%	-3.92%	-0.09%	-0.21%
FCF per Share	-0.11	-0.13	-0.14	-0.67	-0.61	-0.54
FCF Conversion (FCF/Net Income)	0.47x	0.25x	0.38x	0.61x	0.83x	0.99x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-133.66%	-358.66%	-83.62%	-168.75%	-539.76%	-2880.11%
Return on Invested Capital (ROIC)	-	-	-	-987.76%	-	-
Debt / Equity	-	-	0.20x	0.04x	-	0.03x
Interest Coverage	-247.00x	-	-4.84x	-903.47x	-21.91x	-31.84x
FCF Conversion	0.47x	0.25x	0.38x	0.61x	0.83x	0.99x

Frequently Asked Questions

Growth & Financials

NeuroSense Therapeutics Ltd. (NRSN) grew revenue by 0.0% over the past year. Growth has been modest.

NeuroSense Therapeutics Ltd. (NRSN) reported a net loss of $8.7M for fiscal year 2024.

Dividend & Returns

NeuroSense Therapeutics Ltd. (NRSN) has a return on equity (ROE) of -2880.1%. Negative ROE indicates the company is unprofitable.

NeuroSense Therapeutics Ltd. (NRSN) had negative free cash flow of $0.0M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener